CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Revenue of $1.5 million for Q1 2026, up 68.75% sequentially from $864000.0 in Q4 2025, and up 68.55% YoY from $865000.0 in Q1 2025.
CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Revenue for 11 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Revenue rose 68.55% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 89.11% YoY) and the FY2025 annual result came in at $3.5 million, down 90.59% from the prior year.
- Revenue rose to $1.5 million in Q1 2026 per CRSP's latest filing, from $864000.0 in the prior quarter.
- Over five years, Revenue peaked at $201.2 million in Q4 2023 and troughed at $6000.0 in Q4 2022.
- A 5-year average of $25.9 million and a median of $877000.0 in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2023: Revenue sank 99.98% in 2022, then surged 3353333.33% in 2023.
- Over 5 years, Revenue stood at $6000.0 in 2022, then soared by 3353333.33% to $201.2 million in 2023, then slumped by 82.26% to $35.7 million in 2024, then tumbled by 97.58% to $864000.0 in 2025, then jumped by 68.75% to $1.5 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $1.5 million, $864000.0, and $889000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 10.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.18 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 864,000.00 |
| Sep 30, 2025 | 889,000.00 |
| Jun 30, 2025 | 892,000.00 |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | 35.69 Mn |
| Sep 30, 2024 | 602,000.00 |
| Jun 30, 2024 | 517,000.00 |
| Mar 31, 2024 | 504,000.00 |
| Dec 31, 2023 | 201.21 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Mar 31, 2023 | 100.00 Mn |
| Dec 31, 2022 | 6,000.00 |
| Sep 30, 2022 | 94,000.00 |
| Jun 30, 2022 | 158,000.00 |
| Mar 31, 2022 | 940,000.00 |
| Dec 31, 2021 | 12.90 Mn |
| Sep 30, 2021 | 824,000.00 |
| Jun 30, 2021 | 900.70 Mn |